Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
N,N'-Diphenylpyrazolo[1,5-a][1,3,5]triazine-2,4-diamine is a small molecule compound belonging to the pyrazolotriazine class. It is an experimental compound with no approved indications or clinical trials reported. The compound has been studied for its potential biological activities and possible interactions with protein kinases such as casein kinase II subunit alpha (CSNK2A1), but its specific mechanism of action and therapeutic utility remain under investigation. There are no known developers or manufacturers associated with this compound in public records as of current data[1][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on n,n'-diphenylpyrazolo[1,5-a][1,3,5]triazine-2,4-diamine.